These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26748562)

  • 1. Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.
    Abeysekera I; Thomas J; Georgiadis TM; Berman AG; Hammond MA; Dria KJ; Wallace JM; Roper RJ
    Mol Nutr Food Res; 2016 Apr; 60(4):717-726. PubMed ID: 26748562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.
    Goodlett CR; Stringer M; LaCombe J; Patel R; Wallace JM; Roper RJ
    Sci Rep; 2020 Jun; 10(1):10426. PubMed ID: 32591597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
    Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.
    Jamal R; LaCombe J; Patel R; Blackwell M; Thomas JR; Sloan K; Wallace JM; Roper RJ
    PLoS One; 2022; 17(2):e0264254. PubMed ID: 35196359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
    Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome.
    Starbuck JM; Llambrich S; Gonzàlez R; Albaigès J; Sarlé A; Wouters J; González A; Sevillano X; Sharpe J; De La Torre R; Dierssen M; Vande Velde G; Martínez-Abadías N
    Sci Rep; 2021 Feb; 11(1):4715. PubMed ID: 33633179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
    Blazek JD; Abeysekera I; Li J; Roper RJ
    Hum Mol Genet; 2015 Oct; 24(20):5687-96. PubMed ID: 26206885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
    De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
    Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
    McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
    Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup
    Gu Y; Moroy G; Paul JL; Rebillat AS; Dierssen M; de la Torre R; Cieuta-Walti C; Dairou J; Janel N
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.
    Stringer M; Abeysekera I; Dria KJ; Roper RJ; Goodlett CR
    Pharmacol Biochem Behav; 2015 Nov; 138():70-9. PubMed ID: 26363314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usage of and attitudes about green tea extract and Epigallocathechin-3-gallate (EGCG) as a therapy in individuals with Down syndrome.
    Long R; Drawbaugh ML; Davis CM; Goodlett CR; Williams JR; Roper RJ
    Complement Ther Med; 2019 Aug; 45():234-241. PubMed ID: 31331567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model.
    Valenti D; de Bari L; de Rasmo D; Signorile A; Henrion-Caude A; Contestabile A; Vacca RA
    Biochim Biophys Acta; 2016 Jun; 1862(6):1093-104. PubMed ID: 26964795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?
    Wyganowska-Świątkowska M; Matthews-Kozanecka M; Matthews-Brzozowska T; Skrzypczak-Jankun E; Jankun J
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model.
    LaCombe JM; Sloan K; Thomas JR; Blackwell MP; Crawford I; Bishop F; Wallace JM; Roper RJ
    Dis Model Mech; 2024 Sep; 17(9):. PubMed ID: 39136051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compromised femoral and lumbovertebral bone in the Dp(16)1Yey Down syndrome mouse model.
    Lamantia J; Sloan K; Wallace JM; Roper RJ
    Bone; 2024 Apr; 181():117046. PubMed ID: 38336158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development in a Dyrk1a-independent manner.
    Blazek JD; Malik AM; Tischbein M; Arbones ML; Moore CS; Roper RJ
    Mech Dev; 2015 May; 136():133-42. PubMed ID: 25556111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Epigenetic Regulation of Alpha-Synuclein Expression in Down Syndrome.
    Ramakrishna N; Meeker HC; Brown WT
    Mol Neurobiol; 2016 Jan; 53(1):155-162. PubMed ID: 25416858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
    Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
    Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.